Masimo said on Tuesday it has named Becton Dickinson executive Katie Szyman as chief executive officer after a bitter proxy battle with activist hedge fund Politan Capital Management led to the ouster of founder Joe Kiani from the medical device maker's board last year.
MASI's revenue growth in the fourth quarter is likely to have been boosted by the continued robust adoption of its products.
UPPSALA, SWEDEN / ACCESSWIRE / January 13, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) Senzime AB (publ.), a leader in precision-based patient monitoring, today announced that the company has reached a second milestone in its collaboration with Masimo through integration with the Masimo Iris® Gateway.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
MASI, PEN and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar their prospects.
MAMO sees a 30.7% increase in non-GAAP operating income in Q3 2024. Healthcare segment revenues increase 11.5%, driving overall growth amid strategic shifts.
Masimo's third-quarter 2024 results continue to benefit from the strength in its Healthcare business.
Masimo Corporation (NASDAQ:MASI ) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Eli Kammerman - VP of Business Development and IR Michelle Brennan - Interim CEO Micah Young - EVP and CFO Bilal Muhsin - COO Conference Call Participants Jason Bednar - Piper Sandler Marie Thibault - BTIG Michael Polark - Wolfe Research Frederick Wise - Stifel Matt Taylor - Jefferies Vik Chopra - Wells Fargo Michael Matson - Needham Jayson Bedford - Raymond James Operator Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings Conference Call. The company's press release is available at www.masimo.com.
Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Masimo (MASI) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.63 per share a year ago.
Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apple convinced a federal jury on Friday that health monitoring tech company Masimo's smartwatches infringe two of its design patents.